Journal
CIRCULATION RESEARCH
Volume 109, Issue 7, Pages 807-820Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.110.230995
Keywords
drug therapy; genetics; pharmacogenetics; pharmacogenomics
Funding
- U.S. National Institutes of Health [U19 HL065962, U01 GM074492, U01 HL105198, U01 HL069757, R01 DK080007]
- National Institutes of Health for research on antiarrhythmic pharmacogenomics
- Aetna Foundation
- Shire
- Astra Zeneca
- Bristol Myers Squibb
- Merck and Roche
- NIH
Ask authors/readers for more resources
Patients vary in their responses to drug therapy, and some of that variability is genetically determined. This review outlines general approaches used to identify genetic variation that influences drug response. Examples from specific therapeutic areas are presented, such as cholesterol management, arrhythmias, heart failure, hypertension, warfarin anticoagulation, and antiplatelet agents. A brief view of potential pathways to implementation is presented. (Circ Res. 2011; 109: 807-820.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
